Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis

The purpose of this study is to identify a better potential biomarker for the prognosis of patients with non-small cell lung cancer (NSCLC). The expressions of Nek2, MCM7, and Ki-67 were evaluated in 270 NSCLC tissues using immunohistochemical and immunofluorescence techniques. Associations between protein expression and clinical pathologic characters were assessed, and the impact on overall survival was analyzed. We detected high levels of Nek2, MCM7, and Ki-67 expression in 25.9, 35.2, and 24.4 % of NSCLC tissues, respectively. Overexpressions of Nek2 were detected more frequently in high T-stage and N-stage cases (P = 0.000, 0.011). The expressions of Nek2, MCM7, and Ki-67 were correlated with each other. Kaplan-Meier curves indicated that patients with overexpression of Nek2, MCM7, and Ki-67 had a poorer overall survival rate compared to those with low expression for all stages (P = 0.000). In particular, the patients with Nek2 overexpression had the most negative prognosis. Multivariate Cox regression analysis showed that Nek2, MCM7, and Ki-67 are independent prognostic indicators for NSCLC. Our data suggest that among Nek2 kinase, MCM7, and Ki-67, it is Nek2 kinase that is the more effective tumor proliferation marker of poor prognosis for NSCLC patients. Thus, Nek2 may represent a new potential target for NSCLC therapeutic intervention.

[1]  Yi Lu,et al.  Upregulation of NEK2 is associated with drug resistance in ovarian cancer. , 2014, Oncology reports.

[2]  B. Klump,et al.  The prognostic significance of proliferative activity, apoptosis and expression of DNA topoisomerase II alpha in multimodally-treated oesophageal squamous cell carcinoma. , 2001, Anticancer research.

[3]  M. Lei,et al.  Initiating DNA synthesis: from recruiting to activating the MCM complex. , 2001, Journal of cell science.

[4]  M. Yamaguchi,et al.  Nearest neighbour analysis of MCM protein complexes in Drosophila melanogaster. , 2001, Nucleic acids research.

[5]  H. Vesselle,et al.  The Ki‐67 Index and Survival in Non‐‐‐Small Cell Lung Cancer: A Review and Relevance to Positron Emission Tomography , 2002, Cancer journal.

[6]  B. Ponder,et al.  Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer , 2011, Molecular Cancer.

[7]  M. Daidone,et al.  Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.

[8]  P. Lara,et al.  The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  P. Workman,et al.  Identification by High-Throughput Screening of Viridin Analogs as Biochemical and Cell-Based Inhibitors of the Cell Cycle–Regulated Nek2 Kinase , 2010, Journal of biomolecular screening.

[10]  E. F. da Cruz e Silva,et al.  Alternative Splicing Controls Nuclear Translocation of the Cell Cycle-regulated Nek2 Kinase* , 2007, Journal of Biological Chemistry.

[11]  P. Korkolopoulou,et al.  Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymhoma. , 2011, Anticancer research.

[12]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[13]  A. Fry.  The Nek2 protein kinase: a novel regulator of centrosome structure , 2002, Oncogene.

[14]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[15]  R. Muschel,et al.  Inhibition of Centrosome Separation after DNA Damage: A Role for Nek2 , 2004, Radiation research.

[16]  K. Matsuo,et al.  Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-analysis of Randomized Controlled Trials , 2006 .

[17]  O. Poch,et al.  Identification and functional characterization of a new member of the human Mcm protein family: hMcm8. , 2003, Nucleic acids research.

[18]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[19]  M. Caliari,et al.  Minichromosome maintenance 7 protein is a reliable biological marker for human cervical progressive disease , 2012, Journal of gynecologic oncology.

[20]  J. Diffley,et al.  Uninterrupted MCM2-7 function required for DNA replication fork progression. , 2000, Science.

[21]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[22]  Wei-dong Li,et al.  Abnormal expression of Nek2 and β‐catenin in breast carcinoma: clinicopathological correlations , 2011, Histopathology.

[23]  Hisao Ito,et al.  Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication. , 2009, Lung cancer.

[24]  Andrew M Fry,et al.  The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer , 2004, Cancer Research.

[25]  W. Remmele,et al.  Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). , 1993, Pathology, research and practice.

[26]  N. Shepherd,et al.  Ki‐67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations , 1988, The Journal of pathology.

[27]  K. Kao,et al.  Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1 , 2014, Journal of Experimental & Clinical Cancer Research.

[28]  J. Hurwitz,et al.  Processive DNA helicase activity of the minichromosome maintenance proteins 4, 6, and 7 complex requires forked DNA structures. , 2001, Proceedings of the National Academy of Sciences of the United States of America.